Literature DB >> 33522065

Long noncoding RNA CRNDE functions as a diagnostic and prognostic biomarker in osteosarcoma, as well as promotes its progression via inhibition of miR-335-3p.

Yali Yu, Leiming Wang1, Zijun Li1, Yan Zheng1, Zhisong Shi2, Guanghui Wang2.   

Abstract

BACKGROUND: This study was performed to evaluate the diagnostic and prognostic value, as well as the role of long-chain noncoding RNA (lncRNA) colorectal neoplasia differentially expressed (CRNDE) in osteosarcoma (OS).
MATERIALS AND METHODS: A quantitative real-time polymerase chain reaction assay was to determine lncRNA CRNDE and microRNA-335-3p (miR-335-3p) expressions. The Kaplan-Meier analysis was to analyze the relationship between lncRNA CRNDE expression and survival in patients with OS. Receiver operating characteristic curves were to evaluate the diagnostic value of lncRNA CRNDE in OS. Bioinformatics analysis and luciferase reporter assays were used to predict and confirm the relationship between lncRNA CRNDE and miR-335-3p. Cell counting Kit-8 and transwell migration assays assessed the role of lncRNA CRNDE and miR-335-3p in OS cells.
RESULTS: lncRNA CRNDE expression was upregulated and miR-355-3p expression was downregulated in OS. In patients with OS, low lncRNA CRNDE expression demonstrated higher overall survival, whereas high lncRNA CRNDE expression was an independent poor prognostic factor. Furthermore, increased lncRNA CRNDE expression was associated with distant metastasis and the tumor-node-metastasis stage in patients with OS, which can be considered as an independent diagnostic biomarker in OS. We revealed that miR-335-3p was the target of lncRNA CRNDE. It also demonstrated that knockdown of lncRNA CRNDE inhibited OS cell proliferation, migration, and invasion, and inhibition of miR-355-3p promoted this effect. Finally, miR-335-3p partially mediated the stimulatory effects of lncRNA CRNDE in OS.
CONCLUSION: We demonstrated that lncRNA CRNDE is a potential diagnostic and prognostic biomarker for OS, and the lncRNA CRNDE/miR-335-3p axis participates in OS progression.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  OS; lncRNA CRNDE; miR-335-3p; migration; proliferation

Year:  2021        PMID: 33522065     DOI: 10.1002/jbt.22734

Source DB:  PubMed          Journal:  J Biochem Mol Toxicol        ISSN: 1095-6670            Impact factor:   3.642


  6 in total

1.  SNHG15, a p53-regulated lncRNA, suppresses cisplatin-induced apoptosis and ROS accumulation through the miR-335-3p/ZNF32 axis.

Authors:  Yue-Feng Sun; Yuan Wang; Xiao-Dong Li; Hong Wang
Journal:  Am J Cancer Res       Date:  2022-02-15       Impact factor: 6.166

2.  A novel tumor suppressor ASMTL-AS1 regulates the miR-1228-3p/SOX17/β-catenin axis in triple-negative breast cancer.

Authors:  Jie Sun; Xiaohua Li; Enqiao Yu; Jianxia Liu; Liang Sun; Qin He; Qiran Lu
Journal:  Diagn Pathol       Date:  2021-05-18       Impact factor: 2.644

3.  Long non-coding RNA CASC9/microRNA-590-3p axis participates in lutein-mediated suppression of breast cancer cell proliferation.

Authors:  Yuxia Zhang; Jingzhi Chang; Weiwei Jiang; Xin Ye; Shanfeng Zhang
Journal:  Oncol Lett       Date:  2021-05-20       Impact factor: 2.967

4.  circ‑LRP6 contributes to osteosarcoma progression by regulating the miR‑141‑3p/HDAC4/HMGB1 axis.

Authors:  Yali Yu; Guixiang Dong; Zijun Li; Yan Zheng; Zhisong Shi; Guanghui Wang
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

Review 5.  The Roles of Noncoding RNAs in the Development of Osteosarcoma Stem Cells and Potential Therapeutic Targets.

Authors:  Jinxin Liu; Guanning Shang
Journal:  Front Cell Dev Biol       Date:  2022-02-16

6.  Long non-coding RNA long intergenic non-coding 00641 mediates cell progression with stimulating cisplatin-resistance in osteosarcoma cells via microRNA-320d/myeloid cell leukemia-1 axis.

Authors:  JinShan Tang; ZiQiang Zhu; Suwei Dong; YunQing Wang; JianQang Wang; HongLiang Chen; Gang Duan
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.